Mechanism of action and uses of Lynparib/Olaparib

Olaparib/Olaparib (Olaparib) is an oral PARP inhibitor, mainly used to treat certain types of cancer, especially patients with BRCA1 or BRCA2 gene mutations such as ovarian cancer, breast cancer, pancreatic cancer, and metastatic prostate cancer. Its mechanism of action is mainly through inhibiting poly ADP-ribose polymerase (PARP) to exert anti-tumor effects.

In tumor cells,DNA damage is inevitable, and PARP, as an important enzyme, plays a key role in the DNA repair process. When a DNA strand breaks, PARP can quickly recognize and bind to the damaged site, initiate a series of repair reactions, and help cells restore normal functions. However, genes like BRCA1 and BRCA2 are responsible for pathways that repair double-stranded DNA breaks, and when these genes are mutated, the cell's ability to repair them is significantly reduced. Therefore, these tumor cells carrying BRCA mutations are particularly vulnerable when they rely on PARP for single-strand break repair.

Olaparib interferes with the DNA repair process of tumor cells by inhibitingPARP activity, making BRCA mutant cells that lack effective repair mechanisms unable to repair their damaged DNA. This double whammy renders the cancer cells unable to survive and are ultimately eliminated through programmed cell death (apoptosis). In addition, PARP inhibitors can trigger accumulated DNA damage in tumor cells, further promoting cancer cell death.

Clinically, olaparib is mainly used to treat advanced or recurrent ovarian cancer and breast cancer patients withBRCA mutations. In clinical trials, olaparib showed good efficacy, especially in patients whose disease progressed despite chemotherapy. Studies have shown that olaparib can significantly improve progression-free survival (PFS), and is better tolerated by patients and has relatively mild side effects compared with traditional chemotherapy. In addition, Lynparza is also conducting research on the expansion of indications for other types of cancer, including prostate cancer, pancreatic cancer, etc. These cancers may also be associated with BRCA mutations and other related DNA repair mechanism defects.